报 告 人：Prof. Chris Turck，
Head, Proteomics and Biomarkers
Max Planck Institute of Psychiatry
Department of Translational Research in Psychiatry, Germany
报告时间：2018年11月29日 （星期四） 2:00 pm-3:00 pm
报告地点：闵行校区生物药学楼1-105联 系 人：李婧， email@example.com
Research in our laboratory centers on the identification of biosignatures for psychiatric disorders and the antidepressant drug response. Sensitive high throughput proteomics and metabolomics platforms are used for data generation providing a rich source for in silico pathway analyses. Our ultimate goal is to complement imprecise DSM-based clinical parameters with molecular biosignatures to improve patient diagnosis, stratification and treatment.
l Discovery of affected molecular pathways in mouse models that represent defined endophenotypes characteristic for human psychiatric disorders including depression, anxiety, posttraumatic stress disorder and schizophrenia.
l Drugs that target the monoaminergic (SSRI) and glutamatergic (Ketamine) systems studied in mice and non-human primates with the goal to delineate mechanisms relevant for the therapeutic response and novel drug targets.
l Clinical translation with the help of psychiatric patient specimens collected in our hospital.
In addition, we strive to advance our protein and metabolite analysis capabilities in living organisms through the development and implementation of novel methods.
Prof. Chris Turck, Ph.D. is an expert in psychiatric disorders. His research centers on the identification of biosignatures for psychiatric disorders and the antidepressant drug response. He has published more than 250 papers. He serves frequently as committee member in Neuroscience. He also serves on the editorial board of Molecular Neuropsychiatry, Molecular and Cellular Proteomics.